GRFS vs OCSL vs TAK vs ARCC vs GBDC

For growth investors, Oaktree Specialty Lending Corporation (OCSL) is the stronger pick with 60.

9% revenue growth year-over-year, versus 0. 2% for Grifols, S. A. (GRFS). Golub Capital BDC, Inc. (GBDC) offers the better valuation at 9. 3x trailing P/E (9. 2x forward), making it the more compelling value choice. Analysts rate Grifols, S. A. (GRFS) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Golub Capital BDC, Inc.

(GBDC) is the cheapest at 9. 3x versus Takeda Pharmaceutical Company Limited at 77. 4x. On forward P/E, Takeda Pharmaceutical Company Limited is actually cheaper at 0. 2x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Takeda Pharmaceutical Company Limited wins at 0. 01x versus Ares Capital Corporation's 0. 96x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Ares Capital Corporation (ARCC) delivered a total return of +47.

0%, compared to -52. 8% for Grifols, S. A. (GRFS). Over 10 years, the gap is even starker: ARCC returned +139. 2% versus GRFS's -35. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Takeda Pharmaceutical Company Limited (TAK) is the lower-risk stock at 0.

33β versus Grifols, S. A. 's 1. 12β — meaning GRFS is approximately 245% more volatile than TAK relative to the S&P 500. On balance sheet safety, Takeda Pharmaceutical Company Limited (TAK) carries a lower debt/equity ratio of 65% versus 123% for Golub Capital BDC, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Oaktree Specialty Lending Corporation (OCSL) is pulling ahead at 60.

9% versus 0. 2% for Grifols, S. A. (GRFS). On earnings-per-share growth, the picture is similar: Grifols, S. A. grew EPS 147. 8% year-over-year, compared to -45. 8% for Oaktree Specialty Lending Corporation. Over a 3-year CAGR, TAK leads at 8. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Golub Capital BDC, Inc.

(GBDC) is the more profitable company, earning 43. 2% net margin versus 2. 4% for Takeda Pharmaceutical Company Limited — meaning it keeps 43. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GBDC leads at 78. 9% versus 7. 5% for TAK. At the gross margin level — before operating expenses — OCSL leads at 87. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Takeda Pharmaceutical Company Limited (TAK) is the more undervalued stock at a PEG of 0. 01x versus Ares Capital Corporation's 0. 96x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Takeda Pharmaceutical Company Limited (TAK) trades at 0. 2x forward P/E versus 9. 9x for Ares Capital Corporation — 9. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ARCC: 15. 4% to $21. 88.

All stocks in this comparison pay dividends.

Oaktree Specialty Lending Corporation (OCSL) offers the highest yield at 14. 1%, versus 2. 0% for Ares Capital Corporation (ARCC).

For long-horizon retirement investors, Takeda Pharmaceutical Company Limited (TAK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

33), 3. 6% yield). Both have compounded well over 10 years (TAK: -1. 4%, GRFS: -35. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (GRFS (Healthcare) and OCSL (Financial Services) and TAK (Healthcare) and ARCC (Financial Services) and GBDC (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: GRFS is a small-cap deep-value stock; OCSL is a small-cap high-growth stock; TAK is a mid-cap income-oriented stock; ARCC is a mid-cap high-growth stock; GBDC is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.